Who is sponsoring NCT00335101?

NCT00335101 is sponsored by GE Healthcare.

What condition does NCT00335101 study?

NCT00335101 studies Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus.

What drugs are being tested in NCT00335101?

Interventions: Iodixanol, Ioversol, Iopromide.

What is the status of NCT00335101?

NCT00335101 is currently WITHDRAWN.

Last reviewed 2019-04-25 · How we verify

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography

NCT00335101 Phase 4 WITHDRAWN

The study is to evaluate and compare the effects on kidney function of three iodinated contrast media (CM) in patients at risk of kidney damage evaluating serum creatinine (Scr) concentrations up to three days after CM administration.

Details

Lead sponsor	GE Healthcare
Phase	Phase 4
Status	WITHDRAWN
Start date	2006-06

Conditions

Coronary Artery Disease (CAD)
Renal Impairment
Diabetes Mellitus

Interventions

Iodixanol, Ioversol, Iopromide

Primary outcomes

Primary endpoint:
Maximum peak increase in SCr from baseline up to day 3.
Secondary endpoints:
Change in SCr from baseline to day 2 and to day 3
Number of subjects with contrast-induced nephropathy (CIN)
Quality of diagnostic information

Countries

United States, Germany